453
Participants
Start Date
October 19, 2021
Primary Completion Date
November 30, 2027
Study Completion Date
May 31, 2028
R-CHOP
Arm A patients will receive R-CHOP alone.
R-CHOP + acalabrutinib
Arm B patients will receive R-CHOP in combination with acalabrutinib.
Colchester General Hospital, Colchester
East Kent Hospitals NHS Foundation Trust, Canterbury
Monklands Hospital, Airdrie
Victoria Hospital, Blackpool
University Hospital Dorset NHS Foundation Trust (Bournemouth and Poole Hospitals), Bournemouth
Queens Hospital, Burton-on-Trent
Addenbrooke's Hospital, Cambridge
Royal Derby Hospital, Derby
Royal Devon and Exeter Hospital, Exeter
Beatson West of Scotland Cancer Centre, Glasgow
Ipswich Hospital, Ipswich
St James Hospital, Leeds
Leicester Royal Infirmary, Leicester
Chase Farm and Barnet Hospitals, London
Lewisham and Greenwich NHS Trust, London
University College London Hospital, London
Maidstone Hospital, Maidstone
The Christie Hospital, Manchester
Milton Keynes University Hospital, Milton Keynes
Freeman Hospital, Newcastle
Norfolk and Norwich University Hospital, Norwich
Nottingham City Hospital, Nottingham
Royal Oldham Hospital, Oldham
Churchill Hospital, Oxford
Derriford Hospital, Plymouth
Queen Alexandra Hospital, Portsmouth
Queen's Hospital, Romford
Southampton General Hospital, Southampton
Royal Stoke University Hospital, Stoke-on-Trent
Singleton Hospital, Swansea
Torbay Hospital, Torquay
Royal Cornwall Hospital, Truro
Worthing and St Richards Hospitals, Worthing
Collaborators (1)
AstraZeneca
INDUSTRY
University Hospital Southampton NHS Foundation Trust
OTHER